ACTRN12611000153910已完成未知
Early Cardiac Changes During Anthracycline and/or Trastuzumab Therapy in Breast Cancer
Professor Joseph Selvanayagam0 个研究点目标入组 100 人开始时间: 2011年2月9日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- Female
入选标准
- •All patients with new diagnosis of HER2 positive early breast cancer planned for standard chemotherapy with anthracyclines and/or trastuzumab, or, patients with recurrent breast cancer planned for chemotherapy with anthracyclines and/or trastuzumab that have not had chemotherapy in the last 5 years.
排除标准
- •Patients with recurrent breast cancer that have received chemotherapy in the last 5 years, patients that don't meet safety requirements for cardiac MRI.
研究者
相似试验
已完成
不适用
A cohort study of anthracycline-induced cardiotoxicityAll patients scheduled for anthracycline-containing therapy for various kinds of tumorsJPRN-UMIN000022984niversity of Tsukuba500
已完成
不适用
Primary Prevention of Anthracycline-induced Cardiotoxicity with L-Carnitine in patients with breast Cancer (PPACC): pilot studyBreast CancerCancerISRCTN32332192niversity of Ottawa Heart Institute (Institut de cardiologie de l'Université d'Ottawa) (Canada)144
尚未招募
不适用
Pharmacogenomics of anthracycline-induced cardiotoxicity in children with cancerNL-OMON33355Academisch Medisch Centrum80
进行中（未招募）
不适用
Prevention of anthracycline-induced cardiotoxicity: a multicentre randomizedtrial comparing two therapeutic strategies.EUCTR2012-002248-26-ITISTITUTO EUROPEO DI ONCOLOGIA
已完成
不适用
Can we detect early chemotherapy related heart damage in patients with lymphoma using advanced echocardiography?CancerISRCTN84544539South Tees NHS Foundation Trust45